Small intestinal bacterial overgrowth and warfarin dose requirement variability

Area of Science:

• Pharmacology
• Gastroenterology
• Internal Medicine

Background:

• Warfarin dosage varies significantly between patients, influenced by drug interactions and genetics.
• Intestinal flora produces vitamin K2 (VK2); small intestinal bacterial overgrowth (SIBO) is typically associated with reduced vitamin K, not altered INR.
• The relationship between SIBO and warfarin dose requirements remains unclear.

Purpose of the Study:

• To investigate the potential impact of SIBO on warfarin dosage requirements in anticoagulated patients.
• To explore the role of vitamin K metabolism and absorption in patients with varying warfarin needs and SIBO.
• To determine if SIBO prevalence differs across warfarin dose categories.

Main Methods:

• Patients were categorized into low dose (LD), high dose (HD), and very high dose (VHD) warfarin groups based on weekly dosage.
• SIBO was diagnosed using a lactulose breath test.
• Plasma levels of warfarin and vitamin K analogues (VK1, VK2) were measured.

Main Results:

• SIBO prevalence was significantly higher in the VHD group (50%) compared to HD (10%) and LD (0%) groups (P=0.01).
• Predisposing factors for SIBO were more common in the VHD group; other warfarin-influencing factors were not.
• VHD patients had higher plasma VK1 levels and tended to have lower VK2 levels.

Conclusions:

• SIBO may necessitate higher warfarin doses, potentially by enhancing dietary vitamin K1 absorption via compromised intestinal mucosa.
• The study suggests altered VK1 absorption, rather than changes in VK2 biosynthesis, is the likely mechanism.
• Further research with larger cohorts and SIBO treatment is needed to validate these findings.